Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease [Phase 2]

View source ↗

Summary

AbbVie is conducting a Phase 2 study to assess adverse events and changes in disease activity in adults with post-adjuvant ctDNA-positive colorectal cancer and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Telisotuzumab Adizutecan (Telisotuzumab Adizutecan)

Snippet

Sponsor: AbbVie | Conditions: Colorectal Cancer | Phase 2 | Status: RECRUITING